Fund moves

Pfizer (PFE): Deerfield Management Company, L.P. exited its position 3.3M shares

Deerfield Management Company, L.P. exited its position in Pfizer, per its Q4 2025 13F.

3.3M
Prior-quarter shares · no longer reported
Holdings as of
Dec 31, 2025
Filed
Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jun 17, 2025Congress · 1 personMembers of Congress: 2 purchases
  2. Dec 19, 2025CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  3. Dec 31, 2025CongressDisclosed sale of PFE — reported range $100,001 - $250,000
  4. Jan 2, 2026Government · Federal Register noticeRevocation of Two Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
  5. Jan 23, 2026Federal contract · $22K obligatedDepartment of Defense awarded Pfizer: $22K obligated to date
  6. Jan 26, 2026Federal contract · $9K obligatedDepartment of Defense awarded Pfizer: $9K obligated to date
  7. Jan 29, 2026Federal contract · $3K obligatedDepartment of Defense awarded Pfizer: $2.8K obligated to date
  8. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  9. Feb 9, 2026Government · Federal Register ruleAir Plan Approval; Connecticut; Revised Format for Materials Incorporated by Reference
  10. Feb 10, 2026CongressDisclosed purchase of PFE — reported range $1,001 - $15,000

What came next

  1. Feb 18, 2026Federal contract · $8K obligatedDepartment of Defense awarded Pfizer: $8.2K obligated to date
  2. Feb 19, 2026Government · Federal Register noticeGranting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
  3. Feb 24, 2026FDAFDA drug approval: Braftovi
  4. Feb 24, 2026FDAFDA drug approval: Braftovi
  5. Feb 26, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
  6. Mar 6, 2026FDAFDA drug approval: Xeljanz
  7. Mar 6, 2026FDAFDA drug approval: Xeljanz XR
  8. Mar 9, 2026Government · Federal Register noticeAspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications
  9. Mar 13, 2026CongressDisclosed partial sale of PFE — reported range $1,001 - $15,000
  10. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
  11. Apr 3, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
  12. Apr 8, 2026Federal contract · $15K obligatedDepartment of Defense awarded Pfizer: $15K obligated to date
  13. Apr 23, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  14. Apr 23, 2026Federal contract · $23K obligatedDepartment of Defense awarded Pfizer: $23K obligated to date
  15. May 1, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
  16. May 5, 2026Company filing · Form 8-K · ResultsReported its results
  17. May 13, 2026Federal contract · $25K obligatedDepartment of Defense awarded Pfizer: $25K obligated to date
  18. May 15, 2026Federal contract · $543K obligatedDepartment of Health and Human Services awarded Pfizer: $543K obligated to date
  19. May 20, 2026Federal contract · $2K obligatedDepartment of Defense awarded Pfizer: $2.2K obligated to date
  20. Jun 5, 2026FDAFDA drug approval: Hympavzi
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Pfizer

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PFE page.

How this filing works

Explore the data

Common questions

What does this filing report about Pfizer (PFE) stock?

Deerfield Management Company, L.P. exited its position in Pfizer, per its Q4 2025 13F. Held the prior quarter, no longer listed per its Q4 2025 13F.

When did it happen, and when was it made public?

Holdings as of: Dec 31, 2025. Filed: Feb 17, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Pfizer recently?

For Pfizer, OQRO holds 1 fund holdings report (13F) and 1 federal contract award dated in the last 90 days. They are listed on the PFE page.

Does this mean PFE stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Pfizer

Everything OQRO holds on this company is on its PFE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data